Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M950Revenue $M97.0Net Margin (%)-208.1Altman Z-Score-2.8
Enterprise Value $M1,082EPS $-0.9Operating Margin %-200.1Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-214.6Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio2.8Cash flow > EarningsY
Price/Sales11.55-y EBITDA Growth Rate %--Current Ratio2.9Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-30.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-627.3Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M189ROIC % (ttm)-159.7Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAMichael Price 2015-09-30 Add0.15%$5.81 - $9.89
($7.71)
$ 5.07-34%Add 30.27%716,500
ARIAJoel Greenblatt 2015-06-30 Sold Out $7.9 - $9.71
($8.83)
$ 5.07-43%Sold Out0
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
($7.39)
$ 5.07-31%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
($7.39)
$ 5.07-31%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
($6.28)
$ 5.07-19%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 5.07-13%Reduce -85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 5.07-26%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 5.07-35%Reduce -74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 5.07-2%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 5.07-69%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 5.07-63%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 5.07-54%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 5.07-52%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Panayiotopoulos ParisPresident and CEO 2016-02-01Buy61,099$4.913.26view
Duvall Martin JEVP, CCO 2016-02-01Sell14,667$4.815.41view
CLACKSON TIMOTHY PPresident, R&D, CSO 2016-02-01Sell14,667$4.815.41view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2016-02-01Sell14,667$4.815.41view
Haluska FrankSVP, Clinical R&D, CMO 2016-02-01Sell16,133$4.815.41view
BERSTEIN DAVID LSVP, Chief IP Counsel 2016-02-01Sell14,667$4.815.41view
FITZGERALD EDWARD MExecutive VP, CFO 2016-02-01Sell14,667$4.815.41view
Cantor Maria ESVP, Corporate Affairs 2016-02-01Sell16,133$4.825.19view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-09-28Sell5,000$6.46-21.52view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-09-28Sell5,000$6.46-21.52view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 10 2009 
Weekly CEO Buys Highlight: Citigroup Inc, ARIAD Pharmaceuticals Inc, Bruker BioSciences Corp, Akamai Aug 08 2009 

More From Other Websites
The Medicines Company Appoints Sarissa Capital Management Exec To Its Board Of Directors Feb 03 2016
ARIAD (ARIA) to Move AP32788 into Phase I/II Study in 2Q16 Feb 02 2016
ARIAD to Webcast Conference Call on Fourth Quarter and Year-End 2015 Financial Results Feb 02 2016
Ariad Announces FDA Has Given Clearance To Begin Clinical Development Trial Feb 01 2016
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788 Feb 01 2016
ARIAD Announces FDA Clearance to Begin Clinical Development of AP32788 Feb 01 2016
Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Jan 27 2016
Coverage initiated on Ariad Pharm by Barclays Jan 19 2016
ARIAD Pharmaceuticals (ARIA) Stock Gets ‘Underweight’ Rating at Barclays Jan 19 2016
Ariad preps for a sale, but new chairman says it may take time Jan 19 2016
ARIAD Reports Inducement Grant to New Chief Executive Officer Jan 15 2016
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 7.4% Jan 13 2016
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 13 2016
Alex Denner on biotech selloff Jan 12 2016
ARIAD's Iclusig Regulatory Application Filed in Japan Jan 11 2016
ARIAD Announces Termination of Shareholder Rights Plan Jan 11 2016
ARIAD Announces Termination of Shareholder Rights Plan Jan 11 2016
ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors Jan 10 2016
ARIAD Announces Election of Alex Denner as Chairman of the Board of Directors Jan 10 2016
ARIAD and Otsuka Submit New Drug Application in Japan for Ponatinib Jan 08 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK